Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380072 | 0.84 | FPR2 (0.50) | TBXAS1PTGESFPR2 | |
| SCHEMBL9081976 | 0.82 | TERT (0.53) | TERTTBXAS1NAMPTCYP2C19KMT2A | |
| SCHEMBL7426540 | 0.80 | TERT (0.54) | TERTTBXAS1NAMPTFPR2 | |
| SCHEMBL17470979 | 0.79 | SMN1; SMN2 (0.52) | TERTTBXAS1NAMPTKMT2AFPR2 | |
| SCHEMBL434372 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTHRH4FPR2 | |
| SCHEMBL16133628 | 0.78 | TERT (0.49) | TERTTBXAS1NAMPTPTGESFPR2 | |
| SCHEMBL8278814 | 0.77 | TBXAS1 (0.48) | TERTTBXAS1NAMPTTSHR | |
| SCHEMBL28985481 | 0.76 | TBXAS1 (0.51) | TERTTBXAS1NAMPT | |
| SCHEMBL28308832 | 0.76 | TERT (0.46) | TERTTBXAS1NAMPTHRH4FPR2 | |
| SCHEMBL17713588 | 0.76 | TERT (0.46) | TERTTBXAS1NAMPTPTGESHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | TERT 1189/4885TBXAS1 529/4885SPR 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.